Podcast: This Week in Managed Care—Modifiable Risk Factors of Cancer and Other Health News

April 21, 2019

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care news included a study demonstrating that diabetes drug canagliflozin cuts the risk of renal failure and death; the FDA approving the first targeted therapy for metastatic bladder cancer; approximately half of all cancer deaths are attributable to modifiable risk factors.

You may need to log in to the website to access this podcast.

iTunes

TuneIn

Stitcher

Spotify

Listen above or through one of these podcast services:

CREDENCE: Canagliflozin Cuts Risk of Renal Failure, Death 30% in Patients With Type 2 Diabetes, CKD

FDA Approves Erdafitinib, First Targeted Therapy for Metastatic Bladder Cancer

Nearly Half of Cancer Deaths Attributable to Modifiable Risk Factors

Panelists Offer an Insider Perspective of the Unstable Future of Genetic Testing Reimbursement

FLASCO Spring Session 2019

Deaths Among Opioid Users: Impact of Potential Inappropriate Prescribing Practices

The American Journal of Managed Care®—April 2019

Read more about the stories in this podcast: